PABO
Asset Logo

Patrys Limited

πŸ‡¦πŸ‡Ί ASX

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

0
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Patrys Limited - Option Expiring 05-Aug-2023

πŸ“ˆ Performance

Price History

N/A

1M

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

0%
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.00

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in PABO

0

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in PABO

N/A
PABO investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

Pearlers who invest in PABO also invest in...

Want more shares? Try these...

Patrys Limited

PABOA

πŸ“Š Share price

$0.00 AUD
Find Out More

Pacific Current Group Ltd. engages in the business of investing in asset managers, private advisory, placement, and investment related firms. The company is headquartered in Sydney, New South Wales and currently employs 20 full-time employees. The firm provides value to shareholders, investors and partners. The firm invests in asset managers, private advisory, placement and investment-related firms on a global basis. The company also provides, on an as-agreed basis, distribution and management services to specific investee companies. Its portfolio consists of a range of strategies, diversified across investment strategy, geography, revenue model and client type. Its portfolio of companies includes Aether Investment Partners, LLC; Astarte Capital Partners, LLP; Banner Oak Capital Partners LP and other. Aether Investment Partners, LLC is focused on private investments in natural resources, infrastructure and opportunistic real assets. Astarte Capital Partners, LLP is focused on infrastructure, natural resources, transportation and real estate. Banner Oak Capital Partners LP is focused on industrial, multifamily and senior housing sectors.

πŸ“Š Share price

$6.72 AUD

πŸ“Š Share price

$0.01 AUD

Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm focuses on the development of antibody therapies for the treatment of cancer. The company is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. The 3E10 antibody has several unusual biological properties not typically seen in antibodies, such as cancer targeting, blood-brain barrier, cell penetrating and inhibit deoxyribonucleic acid (DNA) damage repair. The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. The company also uses the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The firm is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.

πŸ“Š Share price

$0.01 AUD
Compare
Add to watchlist